Kwon, Hyeuknam
Park, Hyoung Churl
Barrera, Albert Cheto
Rutkove, Seward B.
Sanchez, Benjamin
Funding for this research was provided by:
NRF/MSIT (2020R1F1A1A0107244511)
NIH/NINDS (R41 RNS112029A)
Article History
Received: 10 January 2022
Accepted: 9 May 2022
First Online: 19 May 2022
Competing interests
: Dr. Sanchez holds equity in Haystack Diagnostics, a company that develops clinical needle impedance technology for neuromuscular evaluation. The company has an option to license patented needle impedance technology where the author is named an inventor. He also holds equity and serves as Scientific Advisory Board Member of Ioniq Sciencies, a company that develops clinical impedance technology for early cancer detection. Dr. Sanchez serves as Scientific Advisor to the Board of B-Secur, a company that develops wearable ECG and impedance technology, he also holds equity of the company. He consults for Myolex, Inc., a company that develops surface impedance technology. The company has an option to license patented surface EIM technology where the author is named an inventor. Dr. Sanchez also serves as a consultant to Impedimed, Texas Instruments, Happy Health, Maxim Integrated, and EKO Health companies that develop impedance related technology for consumer use. This study did not employ any relevant company technology.